Yesterday’s CMD provided a thorough walkthrough of ilixadencel, and most importantly, clarifying what top-line data that will be presented from the MERECA study. When it comes to the Q2 earnings, costs were somewhat above our expectations, but this doesn’t change our long-term view of the financing.